FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178788183> ?p ?o ?g. }

• W2178788183 endingPage "345" @default.
• W2178788183 startingPage "337" @default.
• W2178788183 abstract "In spite of improvements of average benefit from adjuvant/neoadjuvant treatments, there are still individual patients with early breast cancer at high risk of relapse. We explored the association with outcome of robust gene cluster-based metagenes linked to proliferation, ER-related genes, and immune response to identify those high-risk patients.A total of 3,847 publicly available gene-expression profiles were analyzed (untreated, N = 826; tamoxifen-treated, N = 685; chemotherapy-treated, N = 1,150). Genes poorly performing in formalin-fixed samples were removed. Outcomes of interest were pathologic-complete response (pCR) and distant metastasis-free survival (DMFS). In ER(+)HER2(-), the proliferation and ER-related metagenes were combined to define three risk groups. In HER2(+) and ER(-)HER2(-) risk groups were defined by tertiles of an immune-related metagene.The high-proliferation/low-ER group of ER(+)HER2(-) breast cancer had significantly higher pCR rate [OR, 5.01 (1.76-17.99), P = 0.005], but poorer outcome [HR = 3.73 (1.63-8.51), P = 0.0018] than the low-proliferation/high-ER. A similar association with outcome applied to patients with residual disease (RD) after neoadjuvant chemotherapy (P = 0.01). In ER(-)HER2(-) and HER2(+) breast cancer, immune metagene in the high tertile was linked to higher pCR [33.7% vs. 11.6% in high and low tertile, respectively; OR, 3.87 (1.79-8.95); P = 0.0009]. In ER(-)HER2(-), after adjuvant/neoadjuvant chemotherapy, 5-year DMFS was 85.4% for high-tertile immune metagene, and 43.9% for low tertile. The outcome association was similar in patients with RD (P = 0.0055). In HER2(+) breast cancer treated with chemotherapy the association with risk of relapse was not significant.We developed metagene-based predictors able to define low and high risk of relapse after adjuvant/neoadjuvant therapy. High-risk patients so defined should be preferably considered for trials with investigational agents." @default.
• W2178788183 created "2016-06-24" @default.
• W2178788183 creator A5001674051 @default.
• W2178788183 creator A5011959458 @default.
• W2178788183 creator A5016673044 @default.
• W2178788183 creator A5024589782 @default.
• W2178788183 creator A5026632453 @default.
• W2178788183 creator A5026775250 @default.
• W2178788183 creator A5029732013 @default.
• W2178788183 creator A5039441026 @default.
• W2178788183 creator A5040640445 @default.
• W2178788183 creator A5050476736 @default.
• W2178788183 creator A5063120064 @default.
• W2178788183 creator A5088725310 @default.
• W2178788183 date "2016-01-14" @default.
• W2178788183 modified "2023-10-10" @default.
• W2178788183 title "Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer" @default.
• W2178788183 cites W1498187417 @default.
• W2178788183 cites W1701849548 @default.
• W2178788183 cites W1961026612 @default.
• W2178788183 cites W1969908200 @default.
• W2178788183 cites W1970453414 @default.
• W2178788183 cites W1979113720 @default.
• W2178788183 cites W1990364400 @default.
• W2178788183 cites W2004377796 @default.
• W2178788183 cites W2004630197 @default.
• W2178788183 cites W2023980114 @default.
• W2178788183 cites W2028236537 @default.
• W2178788183 cites W2028433016 @default.
• W2178788183 cites W2035250779 @default.
• W2178788183 cites W2047902191 @default.
• W2178788183 cites W2053122486 @default.
• W2178788183 cites W2057559260 @default.
• W2178788183 cites W2062889582 @default.
• W2178788183 cites W2072761001 @default.
• W2178788183 cites W2088160256 @default.
• W2178788183 cites W2091248443 @default.
• W2178788183 cites W2097683180 @default.
• W2178788183 cites W2098683355 @default.
• W2178788183 cites W2106434365 @default.
• W2178788183 cites W2106714771 @default.
• W2178788183 cites W2109034705 @default.
• W2178788183 cites W2112434826 @default.
• W2178788183 cites W2113499049 @default.
• W2178788183 cites W2113769864 @default.
• W2178788183 cites W2118413367 @default.
• W2178788183 cites W2118728607 @default.
• W2178788183 cites W2119565091 @default.
• W2178788183 cites W2119878357 @default.
• W2178788183 cites W2120236927 @default.
• W2178788183 cites W2121651329 @default.
• W2178788183 cites W2125396123 @default.
• W2178788183 cites W2126503665 @default.
• W2178788183 cites W2128833198 @default.
• W2178788183 cites W2130598050 @default.
• W2178788183 cites W2130982149 @default.
• W2178788183 cites W2132619562 @default.
• W2178788183 cites W2134148782 @default.
• W2178788183 cites W2134878729 @default.
• W2178788183 cites W2143036691 @default.
• W2178788183 cites W2149668671 @default.
• W2178788183 cites W2156273110 @default.
• W2178788183 cites W2161084802 @default.
• W2178788183 cites W2161630562 @default.
• W2178788183 cites W2166842249 @default.
• W2178788183 cites W2167831515 @default.
• W2178788183 cites W2169360530 @default.
• W2178788183 doi "https://doi.org/10.1158/1078-0432.ccr-15-0757" @default.
• W2178788183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26423797" @default.
• W2178788183 hasPublicationYear "2016" @default.
• W2178788183 type Work @default.
• W2178788183 sameAs 2178788183 @default.
• W2178788183 citedByCount "55" @default.
• W2178788183 countsByYear W21787881832015 @default.
• W2178788183 countsByYear W21787881832016 @default.
• W2178788183 countsByYear W21787881832017 @default.
• W2178788183 countsByYear W21787881832019 @default.
• W2178788183 countsByYear W21787881832020 @default.
• W2178788183 countsByYear W21787881832021 @default.
• W2178788183 countsByYear W21787881832022 @default.
• W2178788183 countsByYear W21787881832023 @default.
• W2178788183 crossrefType "journal-article" @default.
• W2178788183 hasAuthorship W2178788183A5001674051 @default.
• W2178788183 hasAuthorship W2178788183A5011959458 @default.
• W2178788183 hasAuthorship W2178788183A5016673044 @default.
• W2178788183 hasAuthorship W2178788183A5024589782 @default.
• W2178788183 hasAuthorship W2178788183A5026632453 @default.
• W2178788183 hasAuthorship W2178788183A5026775250 @default.
• W2178788183 hasAuthorship W2178788183A5029732013 @default.
• W2178788183 hasAuthorship W2178788183A5039441026 @default.
• W2178788183 hasAuthorship W2178788183A5040640445 @default.
• W2178788183 hasAuthorship W2178788183A5050476736 @default.
• W2178788183 hasAuthorship W2178788183A5063120064 @default.
• W2178788183 hasAuthorship W2178788183A5088725310 @default.
• W2178788183 hasBestOaLocation W21787881831 @default.
• W2178788183 hasConcept C121608353 @default.
• W2178788183 hasConcept C126322002 @default.
• W2178788183 hasConcept C143998085 @default.

• next